Varenicline

Generic Name
Varenicline
Brand Names
Champix, Chantix, Tyrvaya
Drug Type
Small Molecule
Chemical Formula
C13H13N3
CAS Number
249296-44-4
Unique Ingredient Identifier
W6HS99O8ZO
Background

Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A...

Indication

For use as an aid in smoking cessation.

Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.

Associated Conditions
Dry Eye Syndrome (DES)
Associated Therapies
Smoking, Cessation
Clinical Trials
Related News

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets

Completed
Conditions
Smoking Cessation
Interventions
Drug: varenicline
First Posted Date
2007-06-06
Last Posted Date
2012-05-11
Lead Sponsor
Pfizer
Target Recruit Count
3719
Registration Number
NCT00483002

A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers

Phase 1
Completed
Conditions
Smoking Cessation
First Posted Date
2007-04-20
Last Posted Date
2008-11-19
Lead Sponsor
Pfizer
Target Recruit Count
73
Registration Number
NCT00463918
Locations
🇬🇧

Pfizer Investigational Site, Slough, Berkshire, United Kingdom

Study of the Effects of Mecamylamine and Varenicline in Schizophrenia

First Posted Date
2007-04-04
Last Posted Date
2017-03-28
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
89
Registration Number
NCT00455650
Locations
🇺🇸

Freedom Trail Clinic, Massachusetts General Hospital, Boston, Massachusetts, United States

Varenicline Tartrate With Telephone-Based Counseling and/or Internet-Based Counseling in Helping Adults Stop Smoking

Not Applicable
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
First Posted Date
2006-03-10
Last Posted Date
2013-12-19
Lead Sponsor
SRI International
Target Recruit Count
1200
Registration Number
NCT00301145
Locations
🇺🇸

SRI International, Menlo Park, California, United States

🇺🇸

Center for Health Studies, Seattle, Washington, United States

🇺🇸

Free & Clear, Incorporated, Seattle, Washington, United States

Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking

Phase 3
Completed
Conditions
Smoking Cessation
Interventions
Drug: placebo
Drug: Varenicline
First Posted Date
2006-01-27
Last Posted Date
2017-04-05
Lead Sponsor
Pfizer
Target Recruit Count
714
Registration Number
NCT00282984
Locations
🇬🇧

Pfizer Investigational Site, Paisley, United Kingdom

A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation

Phase 3
Completed
Conditions
Smoking Cessation
First Posted Date
2005-09-01
Last Posted Date
2010-09-06
Lead Sponsor
Pfizer
Target Recruit Count
250
Registration Number
NCT00141167
Locations
🇨🇳

Pfizer Investigational Site, Taipei, Taiwan

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy